Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

NCT02947022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped PI left institution.

Conditions

Headache
Cognitive Disturbance
Skin Hyperpigmentation
Arthralgia

Interventions

DRUG: Calcium DTPA
DRUG: Zinc DTPA

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]